Evotec SE 6-K, filed May 6, 2026

Evotec SE (EVO)

6-K 2026-05-06 For: 2026-05-06

Added on May 06, 2026

About this 6-K

Evotec SE filed this 6-K on May 6, 2026.

	Evotec SE

	By:	/s/ Christian Wojczewski
		Name: Christian Wojczewski
		Title: Chief Executive Officer

	Three months ended March 31, 2026												Three months ended March 31, 2025
In k€	D&PD			JEB			Inter-segment Elimina-tions			Evotec Group			D&PD			JEB			Inter-segment Elimina-tions			Evotec Group
Revenue¹⁾		119,800			36,844						156,644			140,590			59,389						199,978
Intersegment revenue		97			—			(97	)		—			2			—			(2	)		—
Cost of Revenue*		(112,721	)		(45,589	)		97			(158,212	)		(119,371	)		(47,373	)		2			(166,742	)
Gross profit (loss)		7,176			(8,744	)		—			(1,569	)		21,221			12,015			—			33,236
Gross margin in %		6	%		(24	)%		—	%		(1	)%		11	%		20	%		—	%		14	%

Research and development*		(10,081	)		—			—			(10,081	)		(14,877	)		(52	)		—			(14,929	)
Selling, general and administrative expenses*		(34,827	)		(8,961	)		—			(43,788	)		(41,179	)		(8,356	)		—			(49,536	)
Other operating income		11,930			527			—			12,457			12,312			665			—			12,977
Other operating expense		(2,823	)		(618	)		—			(3,442	)		(904	)		(660	)		—			(1,564	)
Reorganization costs		(74,974	)		—			—			(74,974	)		(192	)		—			—			(192	)
Operating income (loss)		(103,599	)		(17,797	)		—			(121,396	)		(23,620	)		3,611			—			(20,008	)

Adjusted EBITDA		(9,800	)		(12,051	)		—			(21,851	)		(6,856	)		9,964			—			3,107

in k€ except share and per share data	Three months ended March 31, 2026			Three months ended March 31, 2025
Revenue		156,644			199,978
Cost of Revenue*		(158,212	)		(166,742	)
Gross profit (loss)		(1,569	)		33,236

Operating income (expenses)
Research and development*		(10,081	)		(14,929	)
Selling, general and administrative expenses*		(43,788	)		(49,536	)
Other operating income		12,457			12,977
Other operating expenses		(3,442	)		(1,564	)
Reorganization costs		(74,974	)		(192	)
Total operating income (expenses)		(119,828	)		(53,244	)
Operating income (loss)		(121,396	)		(20,008	)

Non-operating income (expense)
Gain (loss) on investment in financial instruments revaluation		192			—
Share of profit (loss) and revaluation of at-equity investments		(286	)		(571	)
Other financial income		1,793			1,216
Other financial expense		(2,583	)		(2,407	)
Other non-operating income (expense)		100			(8,082	)
Net income (loss) before taxes		(122,180	)		(29,851	)
Income taxes		244			(1,726	)
Net income (loss)		(121,936	)		(31,577	)

Weighted average shares outstanding		177,562,407			177,526,086
Net result per share (basic)		(0.69	)		(0.18	)

in k€	as of March 31, 2026		as of December 31, 2025
ASSETS
Current assets:
Cash and cash equivalents		387,912		418,517
Investments		56,851		57,873
Trade and other receivables		98,259		135,963
Contract assets		35,322		28,295
Inventories		32,982		29,317
Current tax assets		33,470		38,453
Other current financial assets including derivatives		19,020		20,217
Prepaid expenses and other current assets		43,549		30,480
Assets classified as held for sale		3,914		3,830
Total current assets		711,278		762,945

Non-current assets:
Non-current investments and other non-current financial assets		48,965		48,004
Investments in associates and joint ventures		4,346		4,629
Property, plant and equipment		530,840		554,626
Intangible assets and goodwill		305,407		303,936
Deferred tax assets		1,686		2,949
Non-current tax assets		36,873		36,349
Other non-current assets		418		507
Total non-current assets		928,534		951,000
Total assets		1,639,812		1,713,945

in k€	as of March 31, 2026			as of December 31, 2025
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Current financial liabilities		88,615			104,720
Trade and other payables		54,900			64,763
Contract liabilities		111,733			104,849
Deferred income		2,953			3,220
Provisions		130,826			58,543
Current income tax liabilities		9,519			10,578
Other current liabilities		24,828			21,401
Total current liabilities		423,374			368,074

Non-current liabilities:
Non-current financial liabilities		298,847			344,008
Deferred tax liabilities		12,668			14,735
Provisions		64,174			18,035
Contract liabilities		132,079			145,324
Deferred income		7,714			8,350
Other non-current liabilities		1,337			1,715
Total non-current liabilities		516,819			532,167

Stockholders’ equity:
Share capital		177,878			177,779
Treasury shares, at cost		(1,139	)		(1,548	)
Additional paid in capital		1,459,025			1,458,466
Retained Earnings		(897,823	)		(775,887	)
Accumulated other comprehensive income		(38,321	)		(45,106	)
Total stockholders' equity		699,620			813,704
Total liabilities and stockholders’ equity		1,639,812			1,713,945

·	Q1 2026 financial performance: Full-year 2026 guidance confirmed; start to the year as expected with group revenues of €156.6 m (€166.9 m at CER); adj. Group EBITDA of -€21.9 m (-€18.9 m at CER) impacted by one-off effects and foreign exchange headwinds

·	D&PD partnerships progress: Nomination of a first preclinical development candidate in Almirall collaboration; new Gates Foundation grants advancing tuberculosis discovery programs

·	Horizon well on track: Implementation phase commenced with actions underway to streamline operations, reduce cost base and improve utilization; benefits expected to build through 2026

·	Leadership update: Transition to Claire Hinshelwood as Chief Financial Officer, ensuring continued financial stewardship; appointment of Dr. Ingrid Müller as Chief Operating Officer, driving execution

·	Investor and analyst webcast and conference call today: 2 p.m. CET / 1 p.m. GMT / 8 a.m. EDT; details can be found below or at this link